LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics.

AUTOR(ES)

Wise, R

RESUMO

The in vitro activities of LY127935 (LY) were compared with those of other beta-lactam antibiotics. LY was highly active (minimal inhibitory concentration [MIC] range 0.06 to 0.25 micrograms/ml) against the common Enterobacteriaceae (including Providencia stuartiia, Enterobacter, and Serrati marcescens), 8 to 16 times more active than cefoxitin, cefuroxime, or cefazolin, and from one-half to one-eighth as active as cefotaxime (HR756). The activity of LY against Pseudomonas aeruginosa (with MICs of 4 and 64 micrograms/ml for 50 and 90% of test strains, respectively) was essentially similar to that of cefotaxime, but was only one-half as active as CGP 7174/E. LY, cefoxitin, and cefotaxime were essentially equally active against Bacteroides fragilis--each was more active than cefuroxime and cefazolin. Against Staphylococcus aureus, LY (50% MIC and 90% MIC of 4 and 16 micrograms/ml, respectively) was less active than cefotaxime, cefoxitin, or cefuroxime and one-eighth as active as cefazolin. The composition and pH of the culture medium had little effect on the activity of LY, although 7.2 appeared to be the optimum pH.

Documentos Relacionados

• Comparative in vitro activity of 1-oxa-beta-lactam (LY127935) and cefoperazone with other beta-lactam antibiotics against anaerobic bacteria.
• LY127935, a new beta-lactam antibiotic, versus Proteus, Klebsiella, Serratia, and Pseudomonas.
• LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity.
• Effect of temocillin in combination with other beta-lactam antibiotics.
• Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics.